Hematologist/oncologist Dr. Jacqueline Barrientos shares the latest updates in CLL care, including BTK inhibitors, treatment combinations, and more.
Patients facing a chronic lymphocytic leukemia (CLL) diagnosis often encounter complex choices about their next steps in treatment.
Here, Dr. Jacqueline Barrientos, a hematologist and oncologist at Mount Sinai Medical Center in Miami Beach, outlines key considerations for treating the disease and provides an overview of BTK inhibitors and other targeted options.
Dr. Jacqueline C. Barrientos
Mount Sinai Medical Center - Miami Beach
CLL care has transformed dramatically in the past decade, shifting from chemotherapy to targeted drugs that offer deeper remissions, fewer side effects, and even treatment‑free periods for many patients.
Dr. Jacqueline Barrientos
Mount Sinai Medical Center - Miami Beach
Most side effects of BTK inhibitors are manageable, and many improve with time. Bruising, bleeding risk, blood pressure changes, and heart rhythm issues are the ones to watch for and report promptly.
Dr. Jacqueline Barrientos
Mount Sinai Medical Center - Miami Beach
Sometimes patient experience can reveal side effects before the medical literature does, according to Dr. Jacqueline Barrientos, Chief of Hematologic Malignancies at Mount Sinai Medical Center in Miami Beach.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
